Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain (Q43280523)

18 November 2017

title

Effects of low-dose intranasal (S)-ketamine in patients with neuropathic pain (English)

1 reference

18 November 2017

0 references

Volker Huge

1

1 reference

18 November 2017

Meike Lauchart

2

1 reference

18 November 2017

Walter Magerl

3

1 reference

18 November 2017

Gustav Schelling

4

1 reference

18 November 2017

Antje Beyer

5

1 reference

18 November 2017

Detlef Thieme

6

1 reference

18 November 2017

Shahnaz C Azad

7

1 reference

18 November 2017

publication date

3 September 2009

1 reference

18 November 2017

published in

European Journal of Pain

1 reference

18 November 2017

volume

14

1 reference

18 November 2017

issue

4

1 reference

18 November 2017

page(s)

387-394

1 reference

Differential effect of intravenous S-ketamine and fentanyl on atypical odontalgia and capsaicin-evoked pain

18 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Is intranasal ketamine an appropriate treatment for chronic non-cancer breakthrough pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Ketamine as adjuvant to opioids for cancer pain. A qualitative systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Safety and efficacy of intranasal ketamine for the treatment of breakthrough pain in patients with chronic pain: a randomized, double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

NMDA antagonists and neuropathic pain--multiple drug targets and multiple uses

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

The clinical role of NMDA receptor antagonists for the treatment of postoperative pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Pharmacologic management of neuropathic pain: evidence-based recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Ketamine and postoperative pain--a quantitative systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Numbness in clinical and experimental pain--a cross-sectional study exploring the mechanisms of reduced tactile function

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Effects of norketamine enantiomers in rodent models of persistent pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Interaction of hyperalgesia and sensory loss in complex regional pain syndrome type I (CRPS I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Pharmacological dissection of the paradoxical pain induced by a thermal grill.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Human surrogate models of neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Effects of the NMDA-receptor antagonist ketamine on perceptual correlates of long-term potentiation within the nociceptive system

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Antihyperalgesic and analgesic properties of the N-methyl-D-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Intraoperative epidural analgesia combined with ketamine provides effective preventive analgesia in patients undergoing major digestive surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Treatment of inflammatory and neuropathic pain by uncoupling Src from the NMDA receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Glutamate-based therapeutic approaches: clinical trials with NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

NMDA receptors as targets for drug action in neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Effects of ketamine on acute somatic nociception in wild-type and N-methyl-D-aspartate (NMDA) receptor epsilon1 subunit knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Cognitive impairment after small-dose ketamine isomers in comparison to equianalgesic racemic ketamine in human volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): Standardized protocol and reference values

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Quantitative sensory testing: a comprehensive protocol for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Quantitative somatosensory thermotest. A key method for functional evaluation of small calibre afferent channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Mechanism-based pain diagnosis: issues for analgesic drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Neuronal plasticity: increasing the gain in pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJPAIN.2009.08.002

10.1016/J.EJPAIN.2009.08.002

21 January 2018

Identifiers

DOI

1 reference

18 November 2017

1 reference